Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Myelofibrosis (MF) Market Revenue Outlook: What CAGR Is Expected Through 2030?
The market for myelofibrosis has experienced consistent expansion. Projections indicate an increase from $1.55 billion in 2025 to $1.6 billion in 2026, reflecting a compound annual growth rate of 3.2%. Factors contributing to the historical growth trajectory include a scarcity of therapeutic alternatives, the significant incidence of anemia among myelofibrosis patients, an upward trend in autoimmune disorders, escalating diagnostic complexities, and a prevalent reliance on corticosteroid therapies for disease management.
The market for myelofibrosis is projected for consistent expansion over the upcoming years, reaching an estimated valuation of $1.8 billion by 2030. This growth trajectory represents a compound annual growth rate (CAGR) of 3.0%. Key factors propelling this market forward during the forecast period include progress in the development of JAK inhibitor treatments, the increasing integration of precision medicine strategies, heightened financial investment in research and development within hematology, continued advancements in stem-cell therapy options, and a greater availability of oral targeted therapies. Prominent shifts anticipated within this timeframe involve a broader uptake of therapies centered on JAK inhibitors, a growing inclination towards employing combination treatment regimens, an elevated focus on initiatives for early detection and screening, intensified investigations into stem-cell transplantation and regenerative medicine, and a more frequent utilization of supportive care measures to alleviate the impact of symptoms.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21226&type=smp
Myelofibrosis (MF) Market Growth Factors Supporting Long-Term Expansion
The expansion of the myelofibrosis (MF) market is anticipated to be fueled by the escalating requirement for personalized treatment strategies. These individualized therapies, designed to match specific genetic, environmental, and lifestyle profiles, are becoming increasingly sought after due to breakthroughs in genomics, biotechnology, and data analysis, which facilitate more accurate and effective care. Myelofibrosis (MF) itself serves as a vital foundation for advancing these targeted treatments by pinpointing crucial molecular pathways, like the JAK-STAT signaling pathway. This understanding allows for the creation of precision medicines, such as JAK inhibitors (including Ruxolitinib, Fedratinib, and Pacritinib), aimed at alleviating symptoms and slowing the advancement of the condition. To illustrate, the American Cancer Society, a non-profit entity in the United States, projected in May 2024 that the nation would see about 81,610 new instances of kidney cancer in 2024 (comprising 52,380 males and 29,230 females), with an estimated 14,390 fatalities (9,450 males and 4,940 females). Consequently, the rising demand for targeted therapies is a primary catalyst for the myelofibrosis (MF) market’s growth.
Myelofibrosis (MF) Market Segment Landscape: Which Areas Lead Market Development?
The myelofibrosis (mf) market covered in this report is segmented –
1) By Drug Type: Jak Inhibitor, Immunomodulators, Hydroxyurea, Other Drug Types
2) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Jak Inhibitor: Ruxolitinib, Fedratinib, Momelotinib, Itacitinib
2) By Immunomodulators: Thalidomide, Lenalidomide, Pomalidomide
3) By Hydroxyurea: Oral Hydroxyurea, Injectable Hydroxyurea
4) By Other Drug Types: Erythropoiesis-Stimulating Agents (ESAs), Danazol, Monoclonal Antibodies, Chemotherapy Agents
Myelofibrosis (MF) Market Industry Trends Shaping Future Revenue Growth
The myelofibrosis (MF) market is seeing significant innovation from key players who are concentrating their efforts on developing and expanding targeted therapies, including JAK1/JAK2 and ACVR1 inhibitors, with the goal of boosting treatment effectiveness, mitigating disease advancement, and ultimately improving patient prognoses for those afflicted with myelofibrosis. Specifically, JAK1/JAK2 inhibitors work by interfering with the Janus kinase signaling pathway to curb inflammation and normalize aberrant blood cell production characteristic of MF, whereas ACVR1 inhibitors function by blocking the activin receptor-like kinase 2 (ALK2), thereby influencing bone marrow fibrosis and the disease’s trajectory. A notable development occurred in September 2023 when the US Food and Drug Administration (FDA) granted approval to Ojjaara (momelotinib), developed by the UK-based pharmaceutical firm GSK plc, for the management of intermediate- or high-risk myelofibrosis. This therapeutic agent boasts a combined effect, addressing both JAK1/JAK2 and ACVR1 pathways, which aids in modulating inflammatory responses and concurrently elevates hemoglobin levels, thereby lessening the necessity for blood transfusions. This regulatory milestone not only broadens the spectrum of available treatments but also establishes a new benchmark in the care of MF patients experiencing anemia, a significant challenge that has historically lacked adequate solutions in the disease’s therapeutic arena.
Myelofibrosis (MF) Market Industry Leaders And Market Competition
Major companies operating in the myelofibrosis (mf) market are Pfizer Inc, Novartis AG, Incyte Corporation, CTI BioPharma Corp, Karyopharm Therapeutics Inc, Sierra Oncology Inc, Kartos Therapeutics Inc, NS Pharma Inc, Keros Therapeutics Inc, Pharmaxis Ltd, Sumitomo Pharma Oncology, Galecto Biotech AB, Actuate Therapeutics Inc, AbbVie Inc, Bristol‑Myers Squibb Company, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Taiga Biotechnologies Inc, Rigel Pharmaceuticals Inc, Imago BioSciences Inc, Samus Therapeutics Inc.
Access The Complete Myelofibrosis (MF) Market Report:
https://www.thebusinessresearchcompany.com/report/myelofibrosis-mf-global-market-report
Myelofibrosis (MF) Market Regional Outlook: Where Are The Largest Opportunities Located?
North Americawas the largest region in the myelofibrosis (MF) market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the myelofibrosis (mf) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
